Stifel Nicolaus reissued their buy rating on shares of Clovis Oncology, Inc. (NASDAQ:CLVS) in a research report released on Friday, November 3rd. They currently have a $125.00 target price on the biopharmaceutical company’s stock.
Several other research analysts also recently weighed in on the stock. Credit Suisse Group set a $107.00 price target on shares of Clovis Oncology and gave the stock a buy rating in a research report on Tuesday, July 18th. Barclays PLC assumed coverage on shares of Clovis Oncology in a report on Monday, October 23rd. They issued an overweight rating and a $105.00 price objective for the company. Gabelli assumed coverage on shares of Clovis Oncology in a research note on Friday, July 7th. They issued a buy rating and a $125.00 price target for the company. Zacks Investment Research raised shares of Clovis Oncology from a hold rating to a buy rating and set a $105.00 price target for the company in a research note on Wednesday, July 12th. Finally, Royal Bank Of Canada initiated coverage on shares of Clovis Oncology in a research report on Thursday, September 14th. They set a sector perform rating and a $81.00 price objective for the company. Eight investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Clovis Oncology presently has an average rating of Buy and a consensus target price of $86.15.
Clovis Oncology (CLVS) traded down $0.93 during trading hours on Friday, reaching $64.56. 1,120,300 shares of the company’s stock traded hands, compared to its average volume of 1,864,114. Clovis Oncology has a one year low of $33.23 and a one year high of $99.45. The company has a debt-to-equity ratio of 0.94, a quick ratio of 3.16 and a current ratio of 3.19.
Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The firm had revenue of $16.81 million during the quarter, compared to analyst estimates of $21.12 million. Clovis Oncology had a negative return on equity of 122.06% and a negative net margin of 947.47%. During the same quarter last year, the company posted ($1.70) EPS. sell-side analysts anticipate that Clovis Oncology will post -7.31 earnings per share for the current year.
In other news, insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $84.54, for a total value of $253,620.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.50% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Greenwood Capital Associates LLC increased its position in Clovis Oncology by 4.0% during the second quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 212 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in shares of Clovis Oncology in the 2nd quarter worth about $8,708,000. Boston Advisors LLC acquired a new stake in shares of Clovis Oncology in the 2nd quarter worth about $8,332,000. Federated Investors Inc. PA increased its holdings in shares of Clovis Oncology by 27.2% in the 2nd quarter. Federated Investors Inc. PA now owns 29,330 shares of the biopharmaceutical company’s stock worth $2,746,000 after acquiring an additional 6,265 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its holdings in shares of Clovis Oncology by 19.5% in the 2nd quarter. State Board of Administration of Florida Retirement System now owns 23,863 shares of the biopharmaceutical company’s stock worth $2,234,000 after acquiring an additional 3,894 shares during the period. 98.53% of the stock is owned by hedge funds and other institutional investors.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with our FREE daily email newsletter.